test

Michael P DiGiovanna MD, PhD

Associate Professor of Medicine (Medical Oncology) and of Pharmacology

Clinical Interests

Breast Cancer


Board Certifications

1997
Medical Oncology, Board Certified

Patient Care Locations

michael_digiovannafaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Cancer, Breast - Female, and Breast - MalePhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Breast - Female and Breast - MaleA Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Breast - FemaleA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

More Clinical Trials...

Edit Profile